Editor-in-chief Jonah Comstock caught up with Alexandre LeVert, chairman, CEO, and co-founder of Osivax, on the sidelines of JP Morgan in San Francisco at the beginning of January of this year.&nbs
With TCEs being studied in both hematological and solid tumors (39 and 34 trials respectively), there are now more than one hundred projects in the preclinical stage.
The cell therapy field is showing no signs of slowing down, with huge investment and excitement around next generation products and their clinical validation in solid tumour indica
Novartis looks odds on to extend the indications of its CDK4/6 inhibitor Kisqali into early-stage breast cancer, on the back of data from the phase 3 NATALEE trial reporte